Comprehensive Report: An In-Depth Analysis of Cemdisiran (DB16121)

1.0 Executive Summary and Overview

Cemdisiran is an investigational, first-in-class, subcutaneously administered therapeutic agent poised to redefine the treatment landscape for several complement-mediated diseases. Developed by Alnylam Pharmaceuticals and now under the exclusive worldwide license of Regeneron Pharmaceuticals, Cemdisiran is a small interfering RNA (siRNA) therapeutic that leverages the Nobel Prize-winning science of RNA interference (RNAi) to silence the production of complement component 5 (C5), a pivotal protein in the terminal complement cascade. Its innovative molecular design, featuring a proprietary N-acetylgalactosamine (GalNAc) conjugate, ensures targeted delivery to hepatocytes, the primary source of circulating C5, enabling a profound and exceptionally durable pharmacodynamic effect from an infrequent dosing schedule.

The clinical development program for Cemdisiran is extensive, with compelling data emerging across multiple therapeutic areas. The most significant advance has been in the treatment of generalized myasthenia gravis (gMG), where the pivotal Phase 3 NIMBLE trial demonstrated that Cemdisiran monotherapy, administered as a convenient subcutaneous injection once every 12 weeks, met its primary and key secondary endpoints with robust statistical and clinical significance. Notably, the monotherapy regimen, which achieved approximately 74% complement inhibition, showed numerically superior efficacy compared to a combination regimen with the C5 antibody pozelimab that achieved near-complete (99%) inhibition. This seminal finding suggests that maximal complement blockade is not necessary for optimal outcomes in gMG and may position Cemdisiran with a best-in-class profile, combining strong efficacy with a potentially more favorable safety profile. Based on these results, Regeneron plans a U.S. regulatory submission for Cemdisiran monotherapy in gMG for the first quarter of 2026.

In other indications, the development strategy has been precisely tailored to the underlying pathophysiology. For paroxysmal nocturnal hemoglobinuria (PNH), a disease requiring near-complete complement blockade, early studies demonstrated the insufficiency of monotherapy, leading to a successful strategic pivot to a combination therapy with a C5 antibody inhibitor. In a head-to-head trial, the combination of Cemdisiran and pozelimab demonstrated superior control of intravascular hemolysis compared to the standard-of-care agent ravulizumab. Furthermore, in a Phase 2 study for IgA nephropathy (IgAN), Cemdisiran achieved a clinically meaningful reduction in proteinuria, a key surrogate marker for disease progression, supporting its continued development in complement-mediated renal diseases. An ambitious Phase 3 program is also underway to evaluate Cemdisiran in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The safety profile of Cemdisiran appears highly favorable. Across multiple trials, it has been generally well-tolerated. In the gMG trial, the rate of serious adverse events with monotherapy was notably lower than that observed with placebo. Critically, no cases of meningococcal infection, a known and life-threatening class risk for C5 inhibitors, have been reported in any clinical trial to date.

Collectively, the data position Cemdisiran as a transformative therapeutic candidate. Its unique mechanism of action, durable effect allowing for an unparalleled quarterly dosing regimen in gMG, strong efficacy, and promising safety profile give it the potential to become a cornerstone therapy in the management of multiple complement-mediated disorders.

2.0 Pharmacological Profile and Mechanism of Action

2.1 Drug Identity, Classification, and Molecular Structure

Cemdisiran is a precisely engineered biopharmaceutical agent, classified as a drug conjugate, oligonucleotide, and specifically as a small interfering RNA (siRNA) therapeutic.[1] Its unique identity is cataloged under several standard identifiers, including DrugBank Accession Number DB16121 and Chemical Abstracts Service (CAS) Number 1639264-46-2.[3] Throughout its development, it has also been known by various synonyms and code names, most notably ALN-CC5, as well as AD-62643 and ALN-62643.[1]

The molecular architecture of Cemdisiran is the key to its function. It is a proprietary formulation consisting of a double-stranded siRNA molecule designed to be complementary to the messenger RNA (mRNA) encoding human complement component 5 (C5).[3] This siRNA is covalently linked to a trivalent N-acetylgalactosamine (GalNAc) ligand.[2] The complexity of this conjugate is reflected in the varied molecular formulas reported, with simpler formulas such as

C78​H140​N11​O34​P likely representing a component of the ligand structure, while more extensive formulas like C542​H711​F17​N169​O330​P45​S6​ represent the entire, complex biomolecule.[3]

This GalNAc-siRNA conjugate structure is a sophisticated platform technology pioneered by Alnylam Pharmaceuticals, engineered specifically for high-affinity, targeted delivery to hepatocytes in the liver.[3] This targeting is of paramount importance because the liver is the principal site of synthesis for the vast majority of circulating C5 protein.[3] To enhance its therapeutic properties, the siRNA component undergoes extensive chemical modifications, including Alnylam's Enhanced Stabilization Chemistry (ESC) and 2'-O-methoxyethyl (MOE) substitutions on the ribose sugars of certain nucleotides.[13] These modifications serve a critical purpose: they protect the siRNA molecule from degradation by nucleases present in the bloodstream, thereby increasing its in vivo stability, extending its biological half-life, and ultimately enhancing the potency and durability of its therapeutic effect.[15] This intricate molecular design, which combines a highly specific gene-silencing payload with a liver-targeting delivery system, forms the scientific foundation for Cemdisiran's potent, long-acting pharmacodynamic profile and its viability as a subcutaneously administered therapeutic.

Attribute	Value	Source(s)
Drug Name	Cemdisiran	3
English Name	Cemdisiran	3
DrugBank ID	DB16121	3
Type	Biotech	3
CAS Number	1639264-46-2	3
Synonyms	ALN-CC5, AD-62643, ALN-62643	5
Molecular Formula	C78​H140​N11​O34​P (component) C542​H711​F17​N169​O330​P45​S6​ (full conjugate)	3
Drug Class	Oligonucleotides, Small interfering RNA, Drug conjugates	1
Mechanism of Action Class	RNA interference, Complement C5 inhibitors	1
Originator	Alnylam Pharmaceuticals	1
Developer	Alnylam Pharmaceuticals; Regeneron Pharmaceuticals	1

2.2 The RNAi Pathway for C5 Suppression

Cemdisiran's therapeutic effect is mediated by RNA interference (RNAi), a natural and highly conserved biological process for post-transcriptional gene silencing that was the subject of the 2006 Nobel Prize for Physiology or Medicine.[12] This mechanism operates "upstream" of conventional protein-targeting drugs, such as monoclonal antibodies, by preventing the synthesis of a disease-causing protein at its genetic source.[13]

The process begins following subcutaneous administration of Cemdisiran. The GalNAc ligand on the molecule acts as a high-affinity homing device, binding specifically to the asialoglycoprotein receptor (ASGPR), which is abundantly expressed on the surface of hepatocytes.[3] This binding event triggers receptor-mediated endocytosis, efficiently internalizing the entire Cemdisiran conjugate into the liver cells.

Once inside the hepatocyte cytoplasm, the siRNA duplex is released from the ligand and recognized by a multi-protein nuclease complex known as the RNA-Induced Silencing Complex (RISC).[6] The RISC complex unwinds the siRNA duplex, degrading and discarding the sense (passenger) strand. The antisense (guide) strand, which is meticulously engineered to be perfectly complementary to a specific sequence on the C5 mRNA, remains incorporated within the activated RISC. This activated, siRNA-loaded RISC then functions as a highly specific search-and-destroy machine, scanning the cytoplasm for C5 mRNA transcripts. Upon finding a complementary C5 mRNA molecule, the guide strand hybridizes to it, guiding the nuclease component of RISC (specifically the Argonaute-2 protein) to cleave the mRNA transcript.[6] This cleavage event renders the mRNA non-functional and targets it for rapid degradation by the cell's machinery.

A critical feature of this process is its catalytic nature. After cleaving one mRNA transcript, the activated RISC is released and is free to find and destroy additional C5 mRNA molecules.[17] This catalytic amplification is a key reason for the profound potency and remarkable durability of the drug's effect. By continuously destroying the genetic blueprints for C5, Cemdisiran effectively halts the translation of C5 protein, leading to a deep and sustained suppression of hepatic C5 synthesis and a corresponding reduction in circulating plasma C5 levels.[3] This upstream point of intervention is fundamentally different from that of C5-targeting monoclonal antibodies (e.g., eculizumab, ravulizumab, pozelimab), which function downstream by binding to and neutralizing C5 protein that has already been synthesized and secreted into the bloodstream.

2.3 Role of the Complement System in Target Indications

The complement system is a complex cascade of over 30 proteins that serves as a critical component of the innate immune system, playing essential roles in pathogen clearance, immune complex removal, and inflammation.[20] However, its dysregulation or inappropriate activation is a central pathogenic driver in a range of human diseases. Complement component C5 sits at a crucial nexus of this cascade. Upon activation by C5 convertase enzymes, C5 is cleaved into two highly active fragments: C5a and C5b.[18]

C5a is a potent anaphylatoxin and chemoattractant that promotes inflammation by recruiting and activating immune cells such as neutrophils and monocytes.[21] C5b initiates the terminal complement pathway, binding sequentially with components C6, C7, C8, and multiple copies of C9 to form the Membrane Attack Complex (MAC), also known as C5b-9.[20] The MAC is a pore-forming structure that inserts into cell membranes, leading to osmotic lysis and cell death. While essential for destroying pathogens, aberrant MAC formation on host cells causes significant tissue damage. Cemdisiran, by preventing the synthesis of the parent C5 protein, is designed to block the generation of both pathogenic effectors—C5a and the MAC—thereby addressing the core mechanism of tissue injury across its target indications.[6]

• Generalized Myasthenia Gravis (gMG): In gMG, pathogenic autoantibodies (primarily anti-acetylcholine receptor antibodies) bind to the postsynaptic membrane of the neuromuscular junction. This binding activates the classical complement pathway, leading to localized C5 cleavage and MAC formation. The MAC directly damages the muscle endplate, causing destruction of acetylcholine receptors and disruption of neuromuscular transmission, which manifests clinically as debilitating muscle weakness and fatigue.[18]
• Paroxysmal Nocturnal Hemoglobinuria (PNH): PNH is caused by a somatic mutation in the PIGA gene in a hematopoietic stem cell, leading to a deficiency of all glycosylphosphatidylinositol (GPI)-anchored proteins on the surface of its clonal descendants, including red blood cells. Two of these missing proteins, CD55 and CD59, are crucial complement regulators. Their absence leaves red blood cells exquisitely vulnerable to spontaneous activation of the alternative complement pathway, resulting in unrestrained C5 activation, MAC formation on the cell surface, and massive intravascular hemolysis.[10]
• Immunoglobulin A Nephropathy (IgAN): The pathogenesis of IgAN involves the deposition of galactose-deficient IgA1-containing immune complexes in the glomerular mesangium of the kidneys. These deposits are believed to activate the lectin and alternative complement pathways, leading to local C5 cleavage. The resulting C5a and MAC formation drive glomerular inflammation and injury, resulting in hematuria and proteinuria, which can progress to end-stage kidney disease.[18]
• Geographic Atrophy (GA): While the pathophysiology is complex, a growing body of evidence implicates chronic inflammation and overactivation of the complement system in the pathogenesis of GA, an advanced form of age-related macular degeneration. Complement components have been identified in drusen, and genetic risk factors for AMD are linked to complement pathway genes. It is hypothesized that excessive complement activation, including C5 cleavage and MAC formation, contributes to the death of retinal pigment epithelial cells and photoreceptors, leading to the progressive lesions characteristic of GA.[15]

3.0 Pharmacokinetics, Pharmacodynamics, and Dosing Regimen

3.1 Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Cemdisiran is characteristic of the advanced GalNAc-siRNA conjugate platform and is defined by rapid absorption and clearance from the systemic circulation coupled with efficient and targeted delivery to the liver.[19]

Following subcutaneous administration, Cemdisiran is absorbed quickly, with the median time to maximum plasma concentration (Tmax) occurring between 0.5 and 1.0 hours in healthy volunteers.[10] Once in the plasma, the parent drug is rapidly converted to its major active metabolite, AS(N-2)3'-cemdisiran.[19]

The defining feature of Cemdisiran's ADME profile is its rapid plasma clearance. Both the parent drug and its active metabolite are cleared from the systemic circulation swiftly, with plasma concentrations declining below the lower limit of quantification (LLOQ) within approximately 48 hours post-dose.[19] This rapid clearance is a direct consequence of the drug's design; the GalNAc ligand facilitates highly efficient binding to the ASGPR on hepatocytes, leading to rapid uptake from the blood into the target tissue. As a result, the drug's primary site of distribution and action is the liver, and systemic exposure is transient. Consistent with this liver-centric distribution, renal excretion is minimal, confirming that the kidneys are not a major route of elimination for the intact drug or its active metabolite.[19]

This pharmacokinetic behavior—a short-lived presence in the plasma—stands in stark contrast to its biological effect. The critical pharmacokinetic event is not the systemic exposure profile but the efficiency of the initial delivery to the liver. Once the siRNA payload is internalized by hepatocytes, it engages the intracellular RNAi machinery, initiating a durable pharmacodynamic response that persists long after the drug has been cleared from the circulation.

3.2 Pharmacodynamic Profile: Duration and Magnitude of C5 Suppression

The pharmacodynamic effect of Cemdisiran is characterized by a rapid, profound, dose-dependent, and exceptionally durable suppression of circulating C5 protein.[10] This sustained biological activity, despite the short plasma half-life of the drug, is the cornerstone of its clinical utility and the key enabler of its convenient, infrequent dosing regimens.

In Phase 1 studies involving healthy volunteers and patients with PNH, single or biweekly subcutaneous doses of 600 mg resulted in a greater than 90% reduction in C5 protein levels. This profound suppression began within 21 to 28 days of dosing and, remarkably, was maintained for 10 to 13 months.[19] This demonstrates a long residence time of the active siRNA within the hepatocyte, where it continues to catalytically degrade C5 mRNA long after the initial dose. A dose-response model estimated a maximum C5 reduction of 99% at the 600 mg dose level.[19]

This potent and sustained effect has been consistently observed across different clinical programs:

• In the Phase 2 trial in IgA Nephropathy, patients receiving 600 mg of Cemdisiran every 4 weeks exhibited a mean reduction from baseline in serum C5 of 98.7% at week 32.[18]
• In the Phase 3 NIMBLE trial in gMG, the monotherapy regimen (600 mg every 12 weeks) was associated with an average of 74% inhibition of complement activity. In contrast, the combination therapy arm (cemdisiran 200 mg plus pozelimab 200 mg every 4 weeks) achieved a near-complete inhibition of approximately 99%.[16]

The ability to achieve such a long-lasting pharmacodynamic effect from a single subcutaneous injection represents a significant advantage over traditional biologic therapies, such as monoclonal antibodies, which typically require sustained plasma concentrations to maintain their therapeutic effect and thus necessitate more frequent intravenous or subcutaneous administration.[10] The data from the gMG trial further demonstrate the ability to titrate the level of C5 suppression by adjusting the dose and frequency, allowing for a tailored therapeutic approach based on the specific requirements of the disease being treated.

3.3 Investigated Dosing and Administration

Cemdisiran is formulated as a solution for subcutaneous injection, a route of administration that is generally preferred by patients over intravenous infusion due to its convenience and potential for self-administration at home.[12] The clinical development program has explored a range of doses and frequencies to optimize the therapeutic regimen for each distinct indication, reflecting a sophisticated strategy that tailors the degree of C5 suppression to the underlying disease pathophysiology.

• Generalized Myasthenia Gravis (gMG): The pivotal Phase 3 NIMBLE trial established a highly convenient dosing schedule for monotherapy. Patients in this arm received a subcutaneous injection of 600 mg of Cemdisiran every 12 weeks (quarterly).[26] The combination therapy arm in the same trial utilized a more frequent regimen of 200 mg of Cemdisiran every 4 weeks, administered along with 200 mg of pozelimab.[26] The success of the quarterly monotherapy regimen is a major potential commercial differentiator.
• IgA Nephropathy (IgAN): The Phase 2 trial in patients with IgAN evaluated a regimen of 600 mg of Cemdisiran administered subcutaneously every 4 weeks.[13] This more frequent, higher-intensity regimen was selected to achieve the near-complete C5 suppression deemed necessary to impact glomerular inflammation.
• Paroxysmal Nocturnal Hemoglobinuria (PNH): The dosing in PNH has evolved based on clinical findings. Initial Phase 1/2 studies explored monotherapy with doses of 200 mg or 400 mg administered weekly.[10] After monotherapy was found to be insufficient, the strategy shifted to combination therapy. Subsequent Phase 2 and 3 trials have evaluated a combination regimen that includes 200 mg of Cemdisiran every 4 weeks alongside a C5 antibody like pozelimab.[5]
• Healthy Volunteer Studies: To establish the safety, pharmacokinetic, and pharmacodynamic properties of the drug, a wide range of doses were studied. These included single ascending doses ranging from 50 mg to 900 mg and multiple ascending doses from 100 mg to 600 mg, administered at various frequencies including weekly, biweekly, and monthly.[10]

This evolution in dosing strategy across indications demonstrates a data-driven approach. The ability to achieve robust clinical efficacy in gMG with a quarterly 600 mg dose is a testament to the drug's long duration of action and the unique biology of the disease, while the more intensive regimens used in PNH and IgAN reflect the higher threshold of C5 inhibition required to control the pathology in those conditions.

4.0 Clinical Efficacy and Development Across Indications

The clinical development program for Cemdisiran is notable for its breadth, investigating the therapeutic potential of C5 suppression across a spectrum of complement-mediated diseases in neurology, hematology, nephrology, and ophthalmology. The program has yielded significant positive results, most notably in generalized myasthenia gravis, and has strategically adapted its approach based on emerging data for each indication.

Trial Name/NCT ID	Indication	Phase	Status	Design	Key Endpoints	Source(s)
NIMBLE (NCT05070858)	Generalized Myasthenia Gravis (gMG)	3	Completed	Randomized, Double-Blind, Placebo-Controlled	Change in MG-ADL Score, Change in QMG Score	26
ACCESS-1 (NCT05131204)	Paroxysmal Nocturnal Hemoglobinuria (PNH)	3	Terminated (exploratory cohort completed)	Randomized, Active-Controlled	Percent Change in LDH	50
IgAN Phase 2 (NCT03841448)	IgA Nephropathy (IgAN)	2	Terminated (results reported)	Randomized, Double-Blind, Placebo-Controlled	Percent Change in 24-hour UPCR	18
GA Phase 3 (NCT06541704)	Geographic Atrophy (GA)	3	Recruiting	Randomized, Double-Masked, Placebo-Controlled	Rate of GA Progression	52
PNH Phase 1/2 (NCT02352493)	PNH / Healthy Volunteers	1/2	Completed	Randomized, Placebo-Controlled, Dose-Escalation	Safety, PK/PD, LDH Levels	10

4.1 Generalized Myasthenia Gravis (gMG)

The most advanced and compelling clinical data for Cemdisiran come from its development in generalized myasthenia gravis, a rare autoimmune disorder where complement-mediated damage to the neuromuscular junction causes debilitating muscle weakness.[26]

4.1.1 Pivotal Phase 3 NIMBLE Trial (NCT05070858): Efficacy of Cemdisiran Monotherapy

The NIMBLE trial was a randomized, double-blind, placebo-controlled study that evaluated Cemdisiran in adults with anti-acetylcholine receptor (AChR) antibody-positive gMG.[26] The results for the Cemdisiran monotherapy arm, which utilized a highly convenient 600 mg subcutaneous dose administered once every 12 weeks, were unequivocally positive and demonstrated both statistical significance and profound clinical meaningfulness.

The trial successfully met its primary endpoint at the 24-week assessment point. Patients treated with Cemdisiran monotherapy showed a mean improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score that was 2.30 points greater than the improvement seen in the placebo group (mean change from baseline of -4.52 vs. -2.22; p=0.0005).[26] The MG-ADL is a critical patient-reported outcome measure that assesses the impact of gMG on daily functions such as speaking, swallowing, breathing, and mobility.

Efficacy was further confirmed by the key secondary endpoint, the Quantitative Myasthenia Gravis (QMG) score, a physician-administered assessment of muscle strength. The Cemdisiran monotherapy group demonstrated a placebo-adjusted improvement of 2.77 points (mean change from baseline of -4.24 vs. -1.46; p=0.0015).[41]

Responder analyses provided further evidence of a robust clinical benefit. A significantly higher proportion of patients in the Cemdisiran group achieved a clinically meaningful improvement of at least 3 points on the MG-ADL scale compared to placebo (76.6% vs. 44.1%; p=0.0001).[41] Similarly, nearly half of the patients on Cemdisiran (48.4%) achieved a substantial improvement of at least 5 points on the QMG score, compared to only 19% of patients on placebo (p=0.0006).[41]

These efficacy results are highly competitive within the gMG landscape. The magnitude of the placebo-adjusted MG-ADL improvement (-2.30 points) positions Cemdisiran at the upper end of, or superior to, the efficacy demonstrated by currently approved C5 inhibitors in their respective pivotal trials, which historically reported improvements in the range of 1.6 to 2.1 points.[16] This strong performance establishes Cemdisiran as a potentially best-in-class therapy based on efficacy.

Endpoint	Cemdisiran Monotherapy (600mg Q12W)	Cemdi-Poze Combination (200mg/200mg Q4W)	Placebo	Placebo-Adjusted Difference (p-value)
Change from Baseline in MG-ADL Score	-4.52	-3.96	-2.22	-2.30 (p=0.0005) for Monotherapy -1.74 (p=0.0086) for Combination
Change from Baseline in QMG Score	-4.24	-3.32	-1.46	-2.77 (p=0.0015) for Monotherapy -1.86 (p=0.0348) for Combination
% Patients with ≥3-point MG-ADL Reduction	76.6%	65.7%	44.1%	RR: 1.84 (p=0.0001) for Monotherapy RR: 1.51 (p=0.0135) for Combination
% Patients with ≥5-point QMG Reduction	48.4%	35.8%	19.0%	RR: 2.67 (p=0.0006) for Monotherapy RR: 1.93 (p=0.0367) for Combination
Source: Data compiled from 26

4.1.2 Strategic Insight: Monotherapy vs. Combination Therapy

A pivotal and somewhat unexpected finding from the NIMBLE trial was the relative performance of the monotherapy and combination therapy arms. The combination arm, which paired Cemdisiran with the C5 antibody pozelimab, achieved a near-complete level of complement inhibition (~99%).[16] While this regimen was also effective and met its primary and secondary endpoints, the magnitude of clinical benefit was numerically smaller across all key measures compared to the monotherapy arm, which achieved a lesser degree of inhibition (~74%).[16]

This result carries profound strategic implications. It strongly indicates that in the pathophysiology of gMG, achieving maximal or complete C5 suppression is not necessary for robust efficacy and, in fact, may not be the optimal therapeutic goal.[38] The superior performance of the monotherapy regimen suggests the existence of a therapeutic "sweet spot" where significant clinical benefit is achieved while leaving a portion of the complement system intact, which may contribute to a more favorable safety profile. This finding directly informed Regeneron's decision to pursue regulatory approval for the simpler, more convenient, and more effective monotherapy regimen, a move that streamlines the path to market and enhances the drug's value proposition.[16] The inclusion of both arms in the trial design proved to be a masterstroke, as it not only identified the superior regimen but also generated invaluable scientific knowledge about the role of complement in gMG.

4.2 Paroxysmal Nocturnal Hemoglobinuria (PNH)

The clinical development of Cemdisiran in PNH provides a compelling counterpoint to the gMG program, illustrating a strategy of adapting the therapeutic approach to the specific biological demands of the disease.

4.2.1 Rationale for Combination Therapy

Initial Phase 1/2 studies (NCT02352493) provided a crucial early lesson. In patients with PNH, Cemdisiran monotherapy, despite achieving profound C5 suppression of over 90%, was found to be insufficient to adequately control intravascular hemolysis, as evidenced by persistently elevated lactate dehydrogenase (LDH) levels.[10] This finding underscored that the pathophysiology of PNH demands a near-total blockade of terminal complement activity to prevent the catastrophic breakdown of red blood cells.[38] This led to a critical strategic pivot away from monotherapy and toward a dual-mechanism combination approach. The hypothesis was that by using Cemdisiran to dramatically lower the overall production of C5, a co-administered C5 antibody (like eculizumab or pozelimab) could more effectively neutralize the remaining residual C5, achieving a deeper and more sustained level of inhibition than either agent could alone. Early data supported this, showing that adding Cemdisiran allowed for a reduction in the required dose and/or frequency of eculizumab.[10]

4.2.2 Efficacy in Controlling Hemolysis (ACCESS-1 Trial)

The combination strategy was tested rigorously in the Phase 3 ACCESS-1 trial (NCT05131204), which included an exploratory head-to-head cohort comparing the combination of pozelimab and cemdisiran (poze-cemdi) against the long-acting C5 inhibitor standard-of-care, ravulizumab.[51] The results demonstrated the superiority of the combination therapy in controlling hemolysis.

Across study visits from week 8 to week 26, 96% of patients treated with poze-cemdi achieved adequate LDH control (defined as LDH ≤1.5 times the upper limit of normal), compared to only 80% of patients treated with ravulizumab.[45] The superiority was even more pronounced when looking at LDH normalization (LDH ≤1x ULN), which was achieved by 93% of poze-cemdi patients versus 65% of ravulizumab patients.[45] Pharmacodynamic measurements confirmed that the poze-cemdi combination provided complete and uninterrupted terminal complement inhibition throughout the dosing interval, whereas patients on ravulizumab showed evidence of waning inhibition toward the end of the dosing cycle.[41] These data strongly suggest that the dual-mechanism approach of suppressing C5 production while simultaneously blocking its function may represent a new, more effective standard of care for achieving deep and durable control of PNH.

Indication	Trial	Endpoint	Result	Source(s)
IgA Nephropathy	Phase 2 (NCT03841448)	Placebo-adjusted reduction in 24-hr UPCR (%)	-37.4%	18
PNH	ACCESS-1 (vs. ravulizumab)	% Patients with adequate LDH control	96% (poze-cemdi) vs. 80% (ravulizumab)	51
PNH	ACCESS-1 (vs. ravulizumab)	% Patients with LDH normalization	93% (poze-cemdi) vs. 65% (ravulizumab)	51

4.3 Immunoglobulin A Nephropathy (IgAN)

Cemdisiran's potential in treating complement-mediated renal disease was evaluated in a Phase 2, randomized, double-blind, placebo-controlled study (NCT03841448) in adult patients with IgAN who had persistent high-level proteinuria (>1 g/day) despite being on standard-of-care therapy.[18] Patients were randomized 2:1 to receive either 600 mg of Cemdisiran subcutaneously every 4 weeks or a placebo.

The trial successfully met its primary endpoint. At week 32, patients treated with Cemdisiran demonstrated a placebo-adjusted geometric mean reduction in the 24-hour urine protein-to-creatinine ratio (UPCR) of 37.4%.[13] This reduction in proteinuria is highly clinically relevant, as proteinuria is a well-established surrogate marker for the risk of progression to end-stage kidney disease in patients with IgAN.[13] A higher proportion of patients in the Cemdisiran arm also achieved a ≥50% reduction in proteinuria compared to the placebo arm.[18] The treatment was generally well-tolerated, providing strong proof-of-concept for the therapeutic hypothesis that suppressing hepatic C5 production can mitigate glomerular injury in IgAN. These positive results support the continued clinical development of Cemdisiran for this indication.[13]

4.4 Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)

Representing a major strategic expansion into ophthalmology, Cemdisiran is currently being investigated in a large-scale Phase 3 clinical trial (NCT06541704) for the treatment of Geographic Atrophy secondary to AMD.[52] GA is an advanced, irreversible form of dry AMD for which treatment options are limited. The trial is a multicenter, randomized, double-masked, placebo-controlled study designed to enroll approximately 975 participants.[69]

This ambitious study is evaluating both Cemdisiran monotherapy and Cemdisiran in combination with pozelimab, with both regimens administered systemically via subcutaneous injection.[26] The primary objective is to assess whether systemic C5 suppression can slow the rate of GA lesion progression.[69] The initiation of such a large, late-stage trial signifies a strong belief by Regeneron in the role of the systemic complement system in the pathogenesis of this ocular disease and leverages the company's extensive expertise in the field. This program has the potential to open up a very large market for Cemdisiran and validate its mechanism across a new therapeutic area.[26]

5.0 Comprehensive Safety and Tolerability Analysis

The safety and tolerability of Cemdisiran have been extensively evaluated across its clinical development program, encompassing studies in healthy volunteers and patients with gMG, PNH, and IgAN. The integrated safety data suggest a favorable and manageable profile, particularly for the monotherapy regimen being pursued for gMG.

5.1 Integrated Safety Profile Across Trials

Cemdisiran has been generally well-tolerated in clinical trials, with most adverse events being mild to moderate in severity.[10]

The most comprehensive safety dataset comes from the Phase 3 NIMBLE trial in gMG. In this study, the overall incidence of treatment-emergent adverse events (TEAEs) in the Cemdisiran monotherapy arm (69%) was lower than in both the combination therapy arm (81%) and, notably, the placebo arm (77%).[16]

A more telling metric is the rate of serious TEAEs (SAEs). Here, the Cemdisiran monotherapy arm demonstrated a remarkably low rate of 3%, which was substantially lower than the 9% observed in the combination arm and the 14% observed in the placebo arm.[16] This finding, where an active therapeutic is associated with a lower rate of serious adverse events than placebo, suggests a net protective effect. By effectively controlling the underlying autoimmune disease, Cemdisiran may reduce the incidence of disease-related complications, such as myasthenic crises or hospitalizations, to a degree that outweighs any direct risks of the drug itself.

Furthermore, the tolerability of the monotherapy was excellent, with no patients discontinuing treatment due to adverse events during the 24-week placebo-controlled period.[16]

The safety profile was also favorable in other indications. In the Phase 2 IgAN study, most adverse events were mild or moderate, and no patients discontinued the study or treatment due to an AE.[13] Similarly, in PNH studies, the combination therapy was generally well-tolerated, with most TEAEs being of mild-to-moderate intensity and no discontinuations due to AEs were reported in the Phase 2 combination study.[40]

Adverse Event Category	gMG Monotherapy (%)	gMG Combination (%)	gMG Placebo (%)	IgAN Cemdisiran (%)	IgAN Placebo (%)
Any TEAE	69	81	77	55 (drug-related)	22 (drug-related)
Serious TEAE	3	9	14	0 (drug-related)	0 (drug-related)
Discontinuation due to AE	0	4	10	0	0
Upper Respiratory Tract Infection	12	8	11	N/A	N/A
Headache	5	11	10	N/A	N/A
Injection-Site Reaction	4	8	1	41	22
Worsening of MG	1	5	17	N/A	N/A
Urinary Tract Infection	5	6	3	N/A	N/A
Nasopharyngitis	5	3	4	N/A	N/A
Rash	5	3	1	N/A	N/A
Peripheral Edema	N/A	N/A	N/A	14	11
Source: Data compiled from 13
Note: Data for IgAN reports drug-related TEAEs and AEs ≥10%. N/A indicates data not reported at that level of detail in the provided sources.

5.2 Adverse Events of Special Interest

• Meningococcal Infections: The most significant safety concern for the class of C5 inhibitors is an increased risk of serious and life-threatening infections with encapsulated bacteria, particularly Neisseria meningitidis. This risk is prominent enough to warrant a Boxed Warning on the labels of approved C5 inhibitors like eculizumab, ravulizumab, and pozelimab (for its approved indication).[26] A striking and highly encouraging finding from the Cemdisiran development program is the complete absence of any reported meningococcal infections across all trial arms and indications.[16] This consistent observation strongly suggests that Cemdisiran's mechanism of action—inhibiting C5 synthesis in the liver rather than systemic blockade—and/or the partial complement inhibition achieved with the gMG monotherapy regimen may confer a significant safety advantage, potentially mitigating this severe class-specific risk.
• Injection-Site Reactions (ISRs): As is common with subcutaneously administered therapies, ISRs were frequently reported. In the IgAN trial, they were the most common adverse event, occurring in 41% of Cemdisiran-treated patients. However, these reactions were consistently described as being mild and transient in nature, and did not lead to treatment discontinuations.[14] In the NIMBLE trial, ISRs were reported in 4% of the monotherapy arm and 8% of the combination arm, versus 1% in the placebo arm.[26]
• Other Infections: Common, generally non-serious infections such as upper respiratory tract infection, nasopharyngitis, and urinary tract infection were observed in the clinical trials. In the NIMBLE gMG trial, the incidence of these events in the Cemdisiran monotherapy arm was comparable to or lower than the placebo arm, suggesting that the partial complement inhibition does not lead to a broad increase in susceptibility to common infections.[16]
• Deaths: No deaths occurred during the 24-week, placebo-controlled period of the pivotal NIMBLE trial. During the open-label extension period of the study, two deaths were reported: one patient in the Cemdisiran monotherapy arm died due to pneumonia, and one patient in the combination arm died due to septic shock. It was noted that both of these patients were receiving concomitant immunosuppressive therapies, which are known to increase infection risk.[16] In the Phase 2 IgAN study, one death occurred in the Cemdisiran arm due to cardiorespiratory collapse following bypass surgery; this event was considered by the investigator to be unrelated to the study drug.[13] While all deaths are serious events, they have occurred in the context of long-term studies in patients with serious underlying diseases and comorbidities, and a causal link to Cemdisiran has not been established.

6.0 Regulatory Status and Competitive Landscape

6.1 Development History and Corporate Partnership

Cemdisiran is a product of the pioneering science at Alnylam Pharmaceuticals, a biotechnology company at the forefront of developing RNAi therapeutics.[12] The drug was developed utilizing Alnylam's proprietary Enhanced Stabilization Chemistry (ESC)-GalNAc conjugate delivery platform, which is designed to enhance the potency, durability, and therapeutic index of subcutaneously administered RNAi therapies targeted to the liver.[12]

In 2019, Alnylam entered into a broad strategic collaboration with Regeneron Pharmaceuticals, a global biopharmaceutical company with deep expertise in immunology, rare diseases, and large-scale clinical development and commercialization.[16] This partnership was significantly updated in June 2024, when the two companies entered into an amended and restated C5 License Agreement. This new agreement granted Regeneron an exclusive, worldwide license to take full responsibility for the continued development and future commercialization of Cemdisiran, both as a monotherapy and for use in combination with C5 antibodies like pozelimab.[16]

Under the terms of the amended agreement, Alnylam is eligible to receive regulatory milestone payments and tiered, double-digit royalties on net sales of Cemdisiran as a monotherapy, with royalty rates reaching up to 15%. If Cemdisiran is commercialized as part of a combination product, Alnylam is entitled to a flat, low double-digit royalty on net sales, in addition to commercial milestone payments of up to $325.0 million.[26] This partnership structure leverages the unique strengths of both companies and signifies Regeneron's strong commitment to advancing Cemdisiran toward global markets.

6.2 Global Regulatory Pathway

Cemdisiran is currently an investigational agent and has not been approved by any regulatory authority for any indication.[12] However, following the positive results of the Phase 3 NIMBLE trial, a clear regulatory path has been established for the gMG indication.

• U.S. Food and Drug Administration (FDA): Regeneron has publicly announced its plan to submit a regulatory application to the FDA for Cemdisiran monotherapy for the treatment of adults with gMG. This submission is planned for the first quarter of 2026, pending the outcome of discussions with the agency.[5]
• Orphan Drug Designation (ODD): To incentivize the development of treatments for rare diseases, Cemdisiran has been granted Orphan Drug Designation by major regulatory bodies for several of its target indications. This status provides benefits such as tax credits, exemption from user fees, and a period of market exclusivity following approval (7 years in the U.S. and 10 years in the EU).[82]
• FDA ODD: Granted for the treatment of Myasthenia Gravis (July 5, 2023) and for the treatment of Paroxysmal Nocturnal Hemoglobinuria (February 10, 2022).[9]
• European Medicines Agency (EMA) ODD: Granted for the treatment of primary IgA Nephropathy (August 20, 2021).[3] The EMA has also agreed upon a paediatric investigation plan (PIP) for Cemdisiran for the treatment of PNH as of December 2023.[87]

These designations underscore the significant unmet medical need in these rare disease populations and provide a supportive regulatory framework for Cemdisiran's path to potential approval.

6.3 Competitive Positioning and Market Analysis (Focus on gMG)

Upon potential approval, Cemdisiran will enter a dynamic and increasingly competitive therapeutic landscape for generalized myasthenia gravis. The market currently includes several classes of highly effective, targeted therapies that have raised the standard of care beyond traditional immunosuppressants. Cemdisiran is poised to compete effectively by offering a unique and compelling overall value proposition that combines strong efficacy with unprecedented convenience and a potentially superior safety profile.

Drug Name (Brand)	Class	Mechanism	Route of Administration	Dosing Frequency	Key Efficacy (MG-ADL Change vs. Placebo)
Cemdisiran	siRNA	C5 Production Inhibitor	Subcutaneous	Every 12 Weeks	-2.30
Ultomiris (ravulizumab)	Monoclonal Ab	C5 Inhibitor	Intravenous	Every 8 Weeks	-1.7
Soliris (eculizumab)	Monoclonal Ab	C5 Inhibitor	Intravenous	Every 2 Weeks	-1.9
Zilbrysq (zilucoplan)	Peptide	C5 Inhibitor	Subcutaneous	Daily	-2.09
Vyvgart (efgartigimod)	Ab Fragment	FcRn Inhibitor	Intravenous / Subcutaneous	Weekly for 4-week cycles	-2.0
Rystiggo (rozanolixizumab)	Monoclonal Ab	FcRn Inhibitor	Subcutaneous	Weekly for 6-week cycles	-2.6
Source: Data compiled from.28 Efficacy data are from respective pivotal trials and are for comparative context; direct head-to-head trial data is limited.

Cemdisiran's competitive position is built on several key pillars:

• Unmatched Dosing Convenience: The quarterly (every 12 weeks) subcutaneous administration schedule established in the NIMBLE trial is a transformative advantage.[5] All other approved targeted therapies for gMG require far more frequent administration, ranging from daily self-injections (Zilbrysq) to weekly infusions or injections for treatment cycles (FcRn inhibitors) to bi-weekly or bi-monthly intravenous infusions in a healthcare setting (Soliris, Ultomiris).[39] This dramatic reduction in treatment burden has the potential to be a primary driver of patient and physician preference, fundamentally changing the experience of living with and managing chronic gMG.
• Robust Efficacy: With a placebo-adjusted MG-ADL improvement of -2.30 points, Cemdisiran's efficacy is at the top of the C5 inhibitor class and is highly competitive with the FcRn inhibitor class.[55] While some analyses suggest FcRn inhibitors may have a slight efficacy edge on this single metric [16], treatment decisions are made based on the totality of a drug's profile. Cemdisiran's strong efficacy, combined with its other advantages, makes it a formidable competitor.
• Favorable Safety Profile: The potential for a superior safety profile is a key differentiator. The lower rate of serious adverse events compared to placebo in the NIMBLE trial is a powerful signal.[16] Most importantly, the absence of meningococcal infections to date addresses the most significant safety concern associated with the C5 inhibitor class.[16] This could position Cemdisiran as the C5 inhibitor of choice for risk-averse patients and clinicians and may simplify treatment by potentially reducing the need for mandatory vaccinations and prophylactic antibiotics.
• Novel Mechanism of Action: As the first potential siRNA therapy for gMG, Cemdisiran offers a novel therapeutic approach.[55] This may be appealing for patients who have had an inadequate response to or cannot tolerate antibody-based therapies, or for those who prefer a non-protein-based therapeutic.

In summary, Cemdisiran is not positioned to compete on a single feature but on a comprehensive and highly attractive clinical profile. It has the potential to reshape the gMG market by establishing a new standard for long-term maintenance therapy that combines efficacy, safety, and a paradigm-shifting level of convenience.

7.0 Strategic Analysis and Future Directions

The comprehensive body of evidence on Cemdisiran paints a picture of a highly promising, strategically important therapeutic asset with the potential to become a cornerstone treatment across multiple complement-mediated diseases. A strategic analysis reveals a profile characterized by significant strengths and opportunities, balanced by manageable weaknesses and external threats.

Strengths:

• Novel and Validated Mechanism: Cemdisiran's RNAi-based mechanism for silencing C5 production is innovative, potent, and targets a clinically validated pathway central to multiple diseases.
• Best-in-Class Dosing Convenience: The quarterly subcutaneous dosing regimen for gMG is a transformative advantage over all current and near-term competitors, fundamentally reducing treatment burden.
• Robust Clinical Efficacy: The drug has demonstrated strong, clinically meaningful efficacy in a pivotal Phase 3 trial for gMG, with results that are highly competitive within its class.
• Potentially Superior Safety Profile: The lower rate of serious adverse events compared to placebo in the NIMBLE trial and the consistent absence of class-specific meningococcal infections are powerful safety differentiators.
• Broad Pipeline Potential: Positive data in gMG, PNH (combination), and IgAN, along with an ongoing Phase 3 trial in GA, demonstrate the platform's versatility and create multiple avenues for value creation.

Weaknesses:

• Insufficiency as Monotherapy in PNH: The requirement for combination therapy in high-threshold diseases like PNH adds complexity to development, manufacturing, and commercialization compared to a single-agent approach.
• Common but Mild Adverse Events: Injection-site reactions are frequent, and while typically mild and transient, they could be a factor in patient experience.
• Lack of Long-Term Real-World Data: As an investigational agent, the long-term safety and efficacy profile outside the controlled environment of clinical trials remains to be established.

Opportunities:

• Paradigm Shift in gMG Management: Cemdisiran has the potential to become the preferred long-term maintenance therapy for gMG, shifting the treatment paradigm from frequent interventions to a low-touch, chronic care model.
• Best-in-Class Combination for PNH: The poze-cemdi combination has demonstrated superiority over a current standard of care in controlling hemolysis, positioning it to capture the market for PNH patients, especially those with suboptimal responses to existing therapies.
• Expansion into Large Markets: Successful development in Geographic Atrophy would open a significantly larger market than its current rare disease indications, representing a major growth opportunity.
• Platform Validation: The success of Cemdisiran across multiple indications further validates the Alnylam/Regeneron platform and strategy, de-risking future programs targeting complement-mediated pathways.

Threats:

• Intense Competition: The gMG market is crowded with highly effective C5 and FcRn inhibitors from established pharmaceutical companies, creating a high bar for entry and intense competition for market share.
• Pricing and Market Access: In a competitive environment, securing favorable reimbursement and demonstrating a compelling health-economic value proposition will be critical for commercial success.
• Unforeseen Long-Term Safety Signals: As with any new therapeutic class, the possibility of unforeseen safety issues emerging with long-term, widespread use remains a potential risk.
• Evolving Standard of Care: The rapid pace of innovation in immunology could lead to the emergence of new therapeutic classes or approaches that could challenge Cemdisiran's position in the future.

Future Directions and Conclusion:

Cemdisiran stands at the cusp of becoming a major therapeutic agent. The immediate path forward is clear: a successful regulatory submission and potential approval for gMG monotherapy based on the strength of the NIMBLE trial data. The key to realizing its full potential as a franchise-level asset lies in several key areas. First is the confirmation of its long-term durability and safety profile in the ongoing open-label extension studies, which will be critical for building physician confidence. Second is the successful execution of the ambitious and potentially transformative Phase 3 program in Geographic Atrophy. A positive outcome in this indication would dramatically expand the drug's commercial horizon. Finally, continued development of the combination therapy in PNH will be essential to establish a best-in-class profile in that specific high-need population.

In conclusion, Cemdisiran is more than just another complement inhibitor. It is the product of a sophisticated, next-generation therapeutic platform that has demonstrated the ability to precisely tailor the level of biological intervention to the specific needs of a disease. Its unique combination of robust efficacy, a potentially superior safety profile, and a paradigm-shifting dosing convenience positions it to be a highly disruptive and successful therapy in the management of myasthenia gravis and a valuable new tool for a range of other debilitating complement-mediated diseases.

Works cited

1. Alnylam Pharmaceuticals - Cemdisiran - AdisInsight - Springer, accessed September 4, 2025, https://adisinsight.springer.com/drugs/800042020
2. Cemdisiran (ALN-CC5) | C5 Inhibitor - MedchemExpress.com, accessed September 4, 2025, https://www.medchemexpress.com/cemdisiran.html
3. Cemdisiran, terminal sugar modification- | C78H140N11O34P | CID 126480325 - PubChem, accessed September 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cemdisiran
4. Cemdisiran | CAS NO.:1639264-46-2 - GlpBio, accessed September 4, 2025, https://www.glpbio.com/cemdisiran.html
5. Cemdisiran - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 4, 2025, https://synapse.patsnap.com/drug/6994281d9bec41fd94a6066cf9d0c0ac
6. Definition of cemdisiran - NCI Drug Dictionary - NCI, accessed September 4, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cemdisiran
7. Cemdisiran | RNAi drug | CAS#: 1639264-46-2 I N-acetylgalactosamine (GalNAc) conjugated siRNA I InvivoChem, accessed September 4, 2025, https://www.invivochem.com/cemdisiran.html
8. CAS 1639264-46-2 Cemdisiran - BOC Sciences, accessed September 4, 2025, https://www.bocsci.com/product/cemdisiran-cas-1639264-46-2-72728.html
9. Cemdisiran - Orphanet, accessed September 4, 2025, https://www.orpha.net/en/drug/substance/504663?name=
10. Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10435727/
11. 1639264-46-2|Cemdisiran|BLD Pharm, accessed September 4, 2025, https://www.bldpharm.com/products/1639264-46-2.html
12. Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS), accessed September 4, 2025, https://alnylampharmaceuticalsinc.gcs-web.com/static-files/bb05518f-56b8-47c0-a0b4-e7e9302cd711
13. Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy, accessed September 4, 2025, https://investors.alnylam.com/press-release?id=26771
14. Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy, accessed September 4, 2025, https://investors.alnylam.com/press-release?id=26921
15. How to find the chemical modification of Cemdisiran? - Patsnap Synapse, accessed September 4, 2025, https://synapse.patsnap.com/blog/how-to-find-the-chemical-modification-of-cemdisiran
16. RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial, accessed September 4, 2025, https://www.biopharmadive.com/news/regeneron-myasthenia-gravis-cemdisiran-alnylam-study-results/758607/
17. Mechanism of the RNAi pathway. | Download Scientific Diagram - ResearchGate, accessed September 4, 2025, https://www.researchgate.net/figure/Mechanism-of-the-RNAi-pathway_fig1_51574369
18. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial - PubMed Central, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11020434/
19. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9203406/
20. Complement Component C5 - Creative Biolabs, accessed September 4, 2025, https://www.creative-biolabs.com/complement-therapeutics/complement-component-c5.htm
21. Complement Therapeutic Target-C5 Convertases - Creative Biolabs, accessed September 4, 2025, https://www.creative-biolabs.com/complement-therapeutics/complement-therapeutic-target-c5-convertases.htm
22. Complement component 5 - Wikipedia, accessed September 4, 2025, https://en.wikipedia.org/wiki/Complement_component_5
23. Complement C5 - Homo sapiens (Human) | UniProtKB | UniProt, accessed September 4, 2025, https://www.uniprot.org/uniprotkb/P01031/entry
24. What are C5 modulators and how do they work? - Patsnap Synapse, accessed September 4, 2025, https://synapse.patsnap.com/article/what-are-c5-modulators-and-how-do-they-work
25. Complement C5 Convertase | Sino Biological, accessed September 4, 2025, https://www.sinobiological.com/research/complement-system/c5-convertase
26. Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis, accessed September 4, 2025, https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-phase-3-trial-generalized/
27. The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12110157/
28. A Systematic Review and Meta-analysis (P1-11.007), accessed September 4, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000211026
29. www.neurology.org, accessed September 4, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000211026#:~:text=C5%20inhibitors%2C%20including%20eculizumab%2C%20zilucoplan,protecting%20against%20degradation%20of%20acetylcholine
30. What is Cemdisiran used for? - Patsnap Synapse, accessed September 4, 2025, https://synapse.patsnap.com/article/what-is-cemdisiran-used-for
31. Results from the Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy, accessed September 4, 2025, https://capella.alnylam.com/wp-content/uploads/2022/08/Cemdisiran_EMCHD_Poster_FINAL.pdf
32. Clinical trial paves the way for a potentially new and effective therapy for IgA nephropathy, accessed September 4, 2025, http://www.bcrenal.ca/research/bc-kidney-research-in-focus/2024/clinical-trial-paves-the-way-for-a-potentially-new-and-effective-therapy-for-iga-nephropathy
33. Kidney Week - Abstract Details (2022) - American Society of Nephrology, accessed September 4, 2025, https://www.asn-online.org/education/kidneyweek/2022/program-abstract.aspx?controlId=3797891
34. An Update on Current Therapeutic Options in IgA Nephropathy - MDPI, accessed September 4, 2025, https://www.mdpi.com/2077-0383/13/4/947
35. How does Pozelimabcompare with other treatments for AMD? - Patsnap Synapse, accessed September 4, 2025, https://synapse.patsnap.com/article/how-does-pozelimabcompare-with-other-treatments-for-amd
36. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/33047216/
37. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria - ResearchGate, accessed September 4, 2025, https://www.researchgate.net/publication/346194857_Pharmacokinetic_and_Pharmacodynamic_Properties_of_Cemdisiran_an_RNAi_Therapeutic_Targeting_Complement_Component_5_in_Healthy_Subjects_and_Patients_with_Paroxysmal_Nocturnal_Hemoglobinuria
38. Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis - Drugs.com, accessed September 4, 2025, https://www.drugs.com/clinical_trials/regeneron-announces-positive-results-phase-3-trial-cemdisiran-generalized-myasthenia-gravis-22155.html
39. Treatment Overview | Myasthenia Gravis Foundation of America, accessed September 4, 2025, https://myasthenia.org/treatments/treatment-overview/
40. Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12288694/
41. Regeneron to Submit Application for Cemdisiran in Myasthenia Gravis Following Positive Phase 3 NIMBLE Data - NeurologyLive, accessed September 4, 2025, https://www.neurologylive.com/view/regeneron-submit-application-cemdisiran-myasthenia-gravis-following-positive-phase-3-nimble-data
42. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/38214599/
43. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis - Trials Today, accessed September 4, 2025, https://www.trialstoday.org/trial/NCT05070858
44. Positive Cemdisiran Phase 3 Data Paves Way for Myasthenia Gravis BLA Submission, accessed September 4, 2025, https://www.hcplive.com/view/positive-cemdisiran-phase-3-data-paves-way-myasthenia-gravis-bla-submission
45. Phase III NIMBLE Trial Demonstrates Cemdisiran Efficacy in Generalized Myasthenia Gravis, accessed September 4, 2025, https://www.appliedclinicaltrialsonline.com/view/nimble-trial-demonstrates-cemdisiran-efficacy-generalized-myasthenia-gravis
46. Explore the Latest ISN Global Trials Focus Selection, Featuring a "Trial of the Month" on the Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy, accessed September 4, 2025, https://www.theisn.org/blog/2024/06/18/explore-the-latest-isn-global-trials-focus-selection-featuring-a-trial-of-the-month-on-the-phase-2-trial-of-cemdisiran-in-adult-patients-with-iga-nephropathy/
47. Alnylam stays on Calliditas' heels as Regeneron-partnered nephropathy drug passes phase 2 - Fierce Biotech, accessed September 4, 2025, https://www.fiercebiotech.com/biotech/alnylam-stays-calliditas-heels-passing-phase-2-checkpoint-iga-nephropathy
48. 52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab | Blood | American Society of Hematology, accessed September 4, 2025, https://ashpublications.org/blood/article/142/Supplement%201/2716/502943/52-Week-Open-Label-Extension-Data-from-a-Phase-2
49. A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab | Blood - ASH Publications, accessed September 4, 2025, https://ashpublications.org/blood/article/140/Supplement%201/8174/488847/A-Phase-2-Open-Label-Study-Evaluating-the-Safety
50. Cemdisiran Terminated Phase 3 Trials for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment | DrugBank Online, accessed September 4, 2025, https://go.drugbank.com/drugs/DB16121/clinical_trials?conditions=DBCOND0028737&phase=3&purpose=treatment&status=terminated
51. Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab | Regeneron Pharmaceuticals Inc., accessed September 4, 2025, https://investor.regeneron.com/news-releases/news-release-details/novel-combination-pozelimab-and-cemdisiran-poze-cemdi-achieved/
52. Cemdisiran Recruiting Phase 3 Trials for Dry Macular Degeneration / Age Related Macular Degeneration (ARMD) Treatment - DrugBank, accessed September 4, 2025, https://go.drugbank.com/drugs/DB16121/clinical_trials?conditions=DBCOND0055169%2CDBCOND0067350&phase=3&purpose=treatment&status=recruiting
53. A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy - Clinical Trials, accessed September 4, 2025, https://www.allclinicaltrials.com/study/NCT06541704
54. Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria - ResearchGate, accessed September 4, 2025, https://www.researchgate.net/publication/371886474_Results_of_a_phase_12_study_of_cemdisiran_in_healthy_subjects_and_patients_with_paroxysmal_nocturnal_hemoglobinuria
55. New Hope for Myasthenia Gravis: Regeneron's Cemdisiran Achieves Phase III Success, accessed September 4, 2025, https://bisresearch.com/news/new-hope-for-myasthenia-gravis-regenerons-cemdisiran-achieves-phase-iii-success
56. Regeneron's Phase 3 Trial Shows Positive Results in Myasthenia Gravis, accessed September 4, 2025, https://www.clinicaltrialvanguard.com/news/regenerons-phase-3-trial-shows-positive-results-in-myasthenia-gravis/
57. Cemdisiran Excels in Phase 3 Myasthenia Gravis Trial - Digimed Updates, accessed September 4, 2025, https://digimedupdates.com/cemdisiran-excels-in-phase-3-myasthenia-gravis-trial/
58. Regeneron Reports Positive Result in gMG Study - Global Genes, accessed September 4, 2025, https://globalgenes.org/raredaily/regeneron-reports-positive-result-in-gmg-study/
59. Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis - GlobeNewswire, accessed September 4, 2025, https://www.globenewswire.com/news-release/2025/08/26/3139144/0/en/Regeneron-Announces-Positive-Results-from-Phase-3-Trial-in-Generalized-Myasthenia-Gravis.html
60. Regeneron tees up myasthenia gravis drug approval after Phase III victory, accessed September 4, 2025, https://www.clinicaltrialsarena.com/news/regeneron-myasthenia-gravis-phase-iii/
61. Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis - Stock Titan, accessed September 4, 2025, https://www.stocktitan.net/news/REGN/regeneron-announces-positive-results-from-phase-3-trial-in-c29yeugqscxe.html
62. Regeneron plots 2026 FDA filing after Phase III win in myasthenia gravis - FirstWord Pharma, accessed September 4, 2025, https://firstwordpharma.com/story/5992099
63. Regeneron's Cemdisiran Hits Phase 3 Goals in Myasthenia Gravis, FDA Filing Planned for 2026 - PRISM MarketView, accessed September 4, 2025, https://prismmarketview.com/regenerons-cemdisiran-hits-phase-3-goals-in-myasthenia-gravis-fda-filing-planned-for-2026/
64. Paper: Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition, accessed September 4, 2025, https://ash.confex.com/ash/2024/webprogram/Paper194610.html
65. A Phase 3 Study in PNH Adults who Have Not or Not Recently Received Complement Inhibitor Therapy - Health Research Authority, accessed September 4, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-phase-3-study-in-pnh-adults-who-have-not-or-not-recently-received-complement-inhibitor-therapy/
66. A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment (ACCESS-1) - ClinicalTrials.Veeva, accessed September 4, 2025, https://ctv.veeva.com/study/a-c5-inhibitor-controlled-study-to-evaluate-the-efficacy-and-safety-of-pozelimab-and-cemdisiran-comb
67. A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic, accessed September 4, 2025, https://www.mayo.edu/research/clinical-trials/cls-20467506
68. Study of cemdisiran in adult patients with IgAN - Health Research Authority, accessed September 4, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/study-of-cemdisiran-in-adult-patients-with-igan/
69. A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Clinical Research Trial Listing - CenterWatch, accessed September 4, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06541704/a-study-investigating-subcutaneously-administered-pozelimab-in-combination-with-cemdisiran-or-cemdisiran-alone-in-adult-participants-with-geographic-atrophy
70. Clinical Trials | Retina Center of Texas, accessed September 4, 2025, https://retinacentertx.com/research/clinical-trials
71. Pozelimab + Cemdisiran for Macular Degeneration (SIENNA Trial), accessed September 4, 2025, https://www.withpower.com/trial/phase-3-atrophy-9-2024-8dc36?condition=
72. Clinical Development Pipeline | Alnylam® Pharmaceuticals, accessed September 4, 2025, https://www.alnylam.com/alnylam-rnai-pipeline
73. Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/40708708/
74. Generalized Myasthenia Gravis - ULTOMIRIS® (ravulizumab-cwvz), accessed September 4, 2025, https://ultomiris.com/gmg
75. Phase 3 NIMBLE Trial to Test Effects of Pozelimab and Cemdisiran in Myasthenia Gravis, accessed September 4, 2025, https://www.neurologylive.com/view/phase-3-nimble-trial-test-effects-pozelimab-cemdisiran-myasthenia-gravis
76. A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria | Blood | American Society of Hematology, accessed September 4, 2025, https://ashpublications.org/blood/article/140/Supplement%201/8172/488849/A-Phase-2-Randomized-Trial-Evaluating-the-Safety
77. Paper: 52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab, accessed September 4, 2025, https://ash.confex.com/ash/2023/webprogram/Paper188671.html
78. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial - Mayo Clinic, accessed September 4, 2025, https://mayoclinic.elsevierpure.com/en/publications/phase-2-trial-of-cemdisiran-in-adult-patients-with-iga-nephropath
79. Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity, accessed September 4, 2025, https://investors.alnylam.com/press-release?id=28321
80. Regeneron Reports Phase III Trial Success for Cemdisiran in Treating Generalized Myasthenia Gravis - GeneOnline News, accessed September 4, 2025, https://www.geneonline.com/regeneron-reports-phase-iii-trial-success-for-cemdisiran-in-treating-generalized-myasthenia-gravis/
81. Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win, accessed September 4, 2025, https://www.biospace.com/drug-development/regeneron-eyes-2026-filing-for-sirna-myasthenia-gravis-drug-after-phase-iii-win
82. 21 CFR Part 316 -- Orphan Drugs - eCFR, accessed September 4, 2025, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316
83. Designating an Orphan Product: Drugs and Biological Products - FDA, accessed September 4, 2025, https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
84. Orphan designation: Overview | European Medicines Agency (EMA), accessed September 4, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
85. What is EMA orphan drug designation? - Sciensus, accessed September 4, 2025, https://www.sciensus.com/knowledge-hub/ema-orphan-drug-designation/
86. Union Register of medicinal products - Public health - European Commission, accessed September 4, 2025, https://ec.europa.eu/health/documents/community-register/html/o2489.htm
87. EMEA-003237-PIP02-22 - paediatric investigation plan - European Medicines Agency, accessed September 4, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003237-pip02-22
88. Myasthenia gravis - Diagnosis and treatment - Mayo Clinic, accessed September 4, 2025, https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/diagnosis-treatment/drc-20352040
89. Myasthenia Gravis Treatments | Myasthenia Gravis Foundation of America, accessed September 4, 2025, https://myasthenia.org/myasthenia-gravis-treatments/
90. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10697093/
91. Rozanolixizumab Continues to Show Efficacy, High Responder Rates in Myasthenia Gravis, accessed September 4, 2025, https://www.neurologylive.com/view/rozanolixizumab-continues-show-efficacy-high-responder-rates-myasthenia-gravis